Transcriptome Analyses of Prophage in Mediating Persistent Methicillin-Resistant Staphylococcus aureus Endovascular Infection

Yi Li 1, Liang Chen 2,3*, Fengli Zhu 1, Arnold S. Bayer 1,4 and Yan Q. Xiong 1,4,*

1 The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA 90502, USA
2 Hackensack Meridian Health Center for Discovery and Innovation, Nutley, NJ 07110, USA
3 Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA
4 David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
* Correspondence: yxiong@lundquist.org; Tel.: +31-02-222545

Abstract: Persistent methicillin-resistant Staphylococcus aureus (MRSA) endovascular infections represent a significant subset of S. aureus infections and correlate with exceptionally high mortality. We have recently demonstrated that the lysogenization of prophage $\phi$SA169 from a clinical persistent MRSA bacteremia isolate (300-169) into a clinical resolving bacteremia MRSA isolate (301-188) resulted in the acquisition of well-defined in vitro and in vivo phenotypic and genotypic profiles related to persistent outcome. However, the underlying mechanism(s) of this impact is unknown. In the current study, we explored the genetic mechanism that may contribute to the $\phi$SA169-correlated persistence using RNA sequencing. Transcriptomic analyses revealed that the most significant impacts of $\phi$SA169 were: (i) the enhancement of fatty acid biosynthesis and purine and pyrimidine metabolic pathways; (ii) the repression of galactose metabolism and phosphotransferase system (PTS); and (iii) the down-regulation of the mutual prophage genes in both 300-169 and 301-188 strains. In addition, the influence of different genetic backgrounds between 300-169 and 301-188 might also be involved in the persistent outcome. These findings may provide targets for future studies on the persistence of MRSA.

Keywords: MRSA-persistent infection; prophage; RNA sequencing

1. Introduction

Methicillin-resistant S. aureus (MRSA) is a major cause of life-threatening endovascular infections, including bacteremia and infective endocarditis (IE) [1,2]. Persistent MRSA bacteremia (PB; defined as $\geq$5 days of positive blood cultures in the presence of antibiotic therapy) represents $\sim$15 to 30% of such infections [3,4]. In addition, it is very worrisome that most PB isolates appear to be susceptible in vitro to gold-standard anti-MRSA antibiotics (e.g., vancomycin (VAN) and daptomycin (DAP)) by the Clinical and Laboratory Standards Institute (CLSI) breakpoints [4–6], yet persistent in vivo. Thus, PB represents a uniquely vital variant of traditional antibiotic resistance mechanisms. This problem underscores an urgent need to understand the mechanism(s) of specific factors driving this syndrome.

Prophages can modify their bacterial host’s lifestyle, fitness, virulence, and pathogenesis in numerous ways [7–10]. We recently discovered a novel prophage $\phi$SA169 that exists in a clinical PB isolate (300-169), while is not present in a genetically matched (clonal complex 45 (CC45), agr I, and SCCmec IV) clinical resolving MRSA bacteremia strain (RB, defined as initial MRSA bacteremia resolved within 2–4 days of antibiotic treatment;301-188) [4,11,12]. In addition, whole-genome sequencing (WGS) analyses demonstrated that besides the $\phi$SA169, both PB 300-169 and RB 301-188 strains carry an identical mutual prophage [12]. Importantly, the lysogenization of RB 300-188 by $\phi$SA169 (301-188::$\phi$SA169) leads to this latter construct having “PB-like” phenotypes and genotypes similar to PB 300-169 strain.
both in vitro (e.g., higher growth rate, lower ATP levels, stronger biofilm formation and \(\delta\)-hemolysin activity, earlier activation of global regulators, and higher expression of purine biosynthesis gene \(purF\)) and in an experimental IE model [11]. However, the fundamental mechanisms of the \(\phi\)SA169-driven PB outcomes remain unknown.

The current study aimed to define the impact of \(\phi\)SA169 on genetic factors which may contribute to the PB phenotypes by RNA sequencing (RNA-seq) using PB 300-169 wild type (WT), RB 301-188 WT, and \(\phi\)SA169 lysogenized RB 301-188 (301-188::\(\phi\)SA169) strains. The transcriptomic analyses emphasized genetic factors that might contribute to the PB outcomes and provided clues for future studies on molecular mechanisms of PB outcomes.

2. Materials and Methods
2.1. Bacterial Strains, Plasmids, and Growth Medium

Three MRSA strains, including PB 300-169 WT (300-169), RB 301-188 WT (301-188), and 301-188 WT \(\phi\)SA169 lysogenization (301-188::\(\phi\)SA169), were used in our previous [11] and current studies. The PB 300-169 strain was isolated from a patient with 16 days of persistent MRSA bacteremia, while the RB 301-188 strain was obtained from a patient with 2 days of MRSA bacteremia [4]. In addition, all the three study strains have a minimum inhibitory concentration (MIC) to VAN of 0.5 \(\mu\)g/mL and are susceptible to VAN in vitro based upon the CLSI breakpoints [11]. The strains were routinely grown at 37 \(^\circ\)C in tryptic soy broth (TSB; Becton Dickinson and Company, NJ, USA) or on tryptic soy agar (TSA) plates if not otherwise specified.

2.2. RNA Isolation

RNA isolation was performed following the method described in previous studies [13,14]. In brief, overnight cultured cells of the study strains were pelleted by centrifugation and resuspended in Buffer RLT from RNeasy kit (Qiagen, Germantown, MD, USA), and then transferred into lysing matrix B (MP Biomedicals, Irvine, CA, USA) containing 0.1 mm silica spheres for mechanical lysis using Fastprep (Thermo Fisher, Waltham, MA, USA). Total RNA was isolated according to the manufacturer’s instructions of the RNeasy kit. DNA in the samples was removed using a TURBO™ DNase kit (Thermo Fisher, Waltham, MA, USA) [11]. Biological duplicates from two different experiments were prepared for each study strain. RNA samples with concentrations \(\geq 100\) ng/\(\mu\)L and 260/280 ratio between 1.9 and 2.0 were submitted to the Novogene Corporation Inc (Sacramento, CA, USA) for RNA-seq.

2.3. RNA-Seq and Data Analyses

RNA degradation, purity, integrity, and quantitation were checked prior to the RNA-seq. RNA-seq libraries were constructed using NEBNext®Ultra™ RNA Library Prep Kit for Illumina® (NEB, Ipswich, WA, USA). The index-coded samples were clustered using the PE Cluster Kit cBot-HS (Illumina, San Diego, CA, USA) on a cBot Cluster Generation System. Then, the samples were sequenced, and paired-end reads were obtained. For data analyses, RNA-seq reads were mapped to the genome of the PB 300-169 strain (Accession: JASL0000000) [12] using Bowtie2 [15]. Analyses of differential expressions between any two study strains (two biological replicates per study strain) were performed using DESeq2 R package based on a negative binomial distribution. The resulting \(p\) values were adjusted using Benjamini and Hochberg’s approach for controlling the false discovery rate. The genes with an adjusted \(p\) value (\(p\) adj) \(\leq 0.05\) and \(|\log_2(\text{fold change})| > 0\) were defined as differentially expressed genes (DEGs), indicating the genes had significantly different expression levels in the two strains comparison. The DEGs list generated from the comparison of transcriptomic profiles between the isogenic strain set (301-188 and 301-188::\(\phi\)SA169) indicated the impact of \(\phi\)SA169. In addition, comparisons of 300-169 vs. 301-188 and 300-169 vs. 301-188::\(\phi\)SA169 were also performed to further investigate the role of the distinct genetic backgrounds on the transcriptional changes. The DEGs were
defined as differentially expressed genes (DEGs), indicating the genes that are significantly up- or down-regulated in comparison to the parental strain. The DEGs were classified using the Kyoto Encyclopedia of Genes and Genomes (KEGG) mapper tool with the ST45 mode strain of MRSA CA-347 [16].

2.4. Verification of RNA-Seq Results by qRT-PCR

The expression levels of selected genes from the DEGs listed above were confirmed by qRT-PCR as described previously [11,17,18]. The expression of gyrB was used as a well-studied host gene to normalize transcripts levels, and relative expression was calculated by the ΔΔCT method [5]. The relative expression level was then used to calculate the fold changes in the selected genes in strain comparisons.

3. Results

3.1. Global Analyses of Gene Expression

Each sample yielded a high percentage of exon-mapped reads (85.3–90.1%) that covered over 2000 genes, indicating the abundance of mRNA and low interference from non-coding RNAs. More than 86% of the mapped genes had at least one fragment per kilobase of transcript sequence per million (FPKM), suggesting that the transcriptional profiles covered most of the genes in the study strains. Principal component analysis (PCA) was performed to assess the overall differences in the gene expression of the study strains (Figure 1). Among the study strains, 300-169 had a different genetic background vs. 301-188, while 301-188 and 301-188::φSA169 were isogenic strain-set with the only difference in the absence/presence of φSA169. The strains 301-169 and 301-188 had the most distant locations on the PCA biplot, indicating the most significant genetic variation, while 301-188 and 301-188::φSA169 had the closest locations suggesting minor variation, which might be due to the same genetic background (Figure 1).

The transcriptome profiles of each study strain were compared to identify the DEGs (Figure 2, Table 1). There were 153 DEGs in 301-188::φSA169 vs. 301-188 (Figure 2a), while over 1200 DEGs were found in 300-169 vs. 301-188 (Figure 2b) and 300-169 vs. 301-188::φSA169 (Figure 2c). In the strain 301-188::φSA169, 77 and 76 DEGs were significantly up- and down-regulated, respectively, compared to the parental 301-188 (Table 1). Over half of the up-regulated DEGs (49 out of 77) were the genes of φSA169 (Table S1), while more than one-third of the down-regulated DEGs (24 out of 76) belonged to the
mutual prophage in both 300-169 and 301-188 (Table S2). The high \( \log_2(\text{fold change}) \) values of the 49 \( \phi \)SA169 genes (Table S1) indicated the absence in 301-188. In the 300-169 strain, 666 and 633 DEGs were significantly up- and down-regulated, respectively, compared to 301-188 (Table 1). The detailed up- and down-regulated DEGs in the comparison of 300-169 vs. 301-188 are presented in Tables S3 and S4, respectively. In the comparison of 300-169 vs. 301-188::\( \phi \)SA169, a total of 637 and 613 DEGs were significantly up- and down-regulated, respectively (Table 1). The detailed up- and down-regulated DEGs are presented in Tables S5 and S6, respectively.

![Volcano plots displayed the genes differentially expressed in (a) 301-188::\( \phi \)SA169 vs. 301-188; (b) 300-169 vs. 301-188; (c) 300-169 vs. 301-188::\( \phi \)SA169. The genes with \( p \) adj \( \leq 0.05 \) and \( |\log_2(\text{fold change})| > 0 \) were defined as differentially expressed genes (DEGs) and were labeled in red.](image)

**Figure 2.** Volcano plots displayed the genes differentially expressed in (a) 301-188::\( \phi \)SA169 vs. 301-188; (b) 300-169 vs. 301-188; (c) 300-169 vs. 301-188::\( \phi \)SA169. The genes with \( p \) adj \( \leq 0.05 \) and \( |\log_2(\text{fold change})| > 0 \) were defined as differentially expressed genes (DEGs) and were labeled in red.

**Table 1.** A comparison of differentially expressed genes (DEGs) between the study strains.

|                | No. of Total DEGs | No. of Up-Regulated DEGs | No. of Down-Regulated DEGs |
|----------------|-------------------|--------------------------|---------------------------|
| 301-188::\( \phi \)SA169 vs. 301-188 | 153               | 77                       | 76                        |
| 300-169 vs. 301-188 | 1299              | 666                      | 633                       |
| 300-169 vs. 301-188::\( \phi \)SA169 | 1250              | 637                      | 613                       |

3.2. \( \phi \)SA169 Had Similar Transcriptional Profiles in 300-169 and 301-188::\( \phi \)SA169 Strains

Prophage \( \phi \)SA169 was initially identified in PB 300-169 and transduced into RB 301-188 to construct the 301-188::\( \phi \)SA169 strain. Therefore, \( \phi \)SA169 was an exogenous genomic element for the 301-188 chromosome despite the similar genetic background between 300-169 and 301-188 (e.g., CC45, \( agr \) I, and SCCmec IV); thus, the gene expression of \( \phi \)SA169 may differ in the 300-169 vs. 301-188::\( \phi \)SA169. There were 58 out of a total of 67 annotated genes in \( \phi \)SA169 detected in the current RNA-seq results (Figure 3). The plotted expression levels of \( \phi \)SA169 genes in both 300-169 and 301-188::\( \phi \)SA169 are presented in Figure 3. Bacteriophage (phage) genes are highly mosaic and grouped into different modules based on the functions of the gene products (18). In general, \( \phi \)SA169 genes in the modules of lysogeny, packing and morphogenesis, and lysis were highly expressed, while genes in the replication module had low expression (Figure 3). In addition, the transcriptional profiles of \( \phi \)SA169 were similar in both strains. However, some \( \phi \)SA169 genes, especially in the packing and morphogenesis module, had different expression levels in the two strains, which might imply the impact of the distinct genetic backgrounds.

3.3. The Impact of \( \phi \)SA169 on Transcriptional Profiles

The 301-188::\( \phi \)SA169 and 301-188 formed an isogenic strain set; thus, the DEGs from the comparison of the two strains were likely caused by \( \phi \)SA169. On the other hand, 300-169 and 301-188 strains had distinct genetic backgrounds; thus, the DEGs profile of these two strains might be affected by both \( \phi \)SA169 and their genetic backgrounds. Therefore, the overlapping DEGs between the two comparisons (301-188::\( \phi \)SA169 vs. 301-188 and 300-169 vs. 301-188) might indicate the specific impact of \( \phi \)SA169. There
were total of 65 (29 + 36) DEGs up-regulated (Figure 4a) and 45 (22 + 23) DEGs down-regulated (Figure 4b) by the φSA169. Most up-regulated DEGs (49 out of 65) belonged to φSA169, and the other 16 genes fitted in the MRSA host genes (genes in the chromosome of the study MRSA strains excluding prophage genes) included purA and fatFH (Table 2). Over half of the down-regulated DEGs (24 out of 45) belonged to the mutual prophage in both 300-169 and 301-188 strains, and the remaining 21 DEGs were the MRSA host genes, including lacABCDEF, treP, and pfkB (Table 3).
Table 2. DEGs up-regulated by \( \phi \text{SA169} \).

| Gene Locus  | Group     | \( \text{Log}_{2} \) (Fold Change) | Products                           |
|-------------|-----------|----------------------------------|-----------------------------------|
| AS94_02505  |           | 0.93                             | 0.71 MerR family transcriptional regulator |
| AS94_04115  |           | 0.42                             | 0.72 3-oxoacyl-ACP synthase        |
| AS94_04120  |           | 0.58                             | 1.09 3-oxoacyl-ACP synthase        |
| AS94_04780  |           | 0.51                             | 1.29 amino acid permease           |
| AS94_05160  |           | 0.69                             | 0.86 Na/Pi cotransporter           |
| AS94_05540  |           | 0.44                             | 1.64 glycine/betaine ABC transporter permease |
| AS94_05860  |           | 0.56                             | 0.68 guanine permease              |
| AS94_06080  |           | 0.66                             | 1.52 hypothetical protein          |
| AS94_06090  |           | 0.50                             | 0.70 octopine dehydrogenase        |
| AS94_06310  |           | 0.48                             | 1.09 sodium:glutamate symporter    |
| AS94_07385  |           | 0.71                             | 1.00 transglycosylase              |
| AS94_08925  |           | 0.50                             | 0.51 DEAD/DEAH box helicase        |
| AS94_11275  |           | 0.47                             | 2.59 purA, adenyllosuccinate synthetase |
| AS94_11985  |           | 0.42                             | 0.93 multidrug ABC transporter     |
| AS94_12030  |           | 0.37                             | 0.70 general stress protein        |
| AS94_12101  |           | 0.42                             | 1.23 ribonuclease BN                |
| AS94_12040  |           | 7.11                             | 8.46 hypothetical protein          |
| AS94_12045  |           | 12.65                            | 12.89 XRE family transcriptional regulator |
| AS94_12050  |           | 10.26                            | 11.22 hypothetical protein         |
| AS94_12055  |           | 9.94                             | 10.84 autolysin                    |
| AS94_12060  |           | 7.65                             | 8.65 holin                         |
| AS94_12065  |           | 8.70                             | 9.21 hypothetical protein          |
| AS94_12070  |           | 10.97                            | 11.98 tail protein                 |
| AS94_12075  |           | 11.73                            | 12.79 cell wall hydrolase          |
| AS94_12080  |           | 8.84                             | 9.51 hypothetical protein          |
| AS94_12090  |           | 7.30                             | 8.65 hypothetical protein          |
| AS94_12095  |           | 11.29                            | 12.19 hypothetical protein         |
| AS94_12100  |           | 11.76                            | 12.57 minor structural protein      |
| AS94_12105  |           | 11.63                            | 12.72 peptidase                    |
| AS94_12110  |           | 10.25                            | 11.46 phage tail protein           |
| AS94_12115  |           | 13.07                            | 13.92 membrane protein             |
| AS94_12120  |           | 8.67                             | 9.90 hypothetical protein          |
| AS94_12125  |           | 9.20                             | 10.46 hypothetical protein         |
| AS94_12130  |           | 11.18                            | 12.24 tail protein                 |
| AS94_12135  |           | 8.78                             | 9.81 \( \phi_{11}\_gp38 \)          |
| AS94_12140  |           | 7.89                             | 9.24 hypothetical protein          |
| AS94_12145  |           | 7.15                             | 8.87 hypothetical protein          |
| AS94_12150  |           | 8.69                             | 10.26 phage head-tail adapter protein |
| AS94_12155  |           | 6.85                             | 8.35 \( \phi_{11}\_gp35 \)          |
| AS94_12160  |           | 11.81                            | 12.91 hypothetical protein         |
| AS94_12165  |           | 11.97                            | 13.41 phage capsid protein         |
| AS94_12170  |           | 6.29                             | 7.51 hypothetical protein          |
| AS94_12175  |           | 11.21                            | 12.22 phage head morphogenesis protein |
| AS94_12180  |           | 11.61                            | 12.56 phage portal protein         |
| AS94_12185  |           | 10.89                            | 12.01 hypothetical protein         |
| AS94_12190  |           | 10.14                            | 11.07 terminase                    |
| AS94_12195  |           | 10.04                            | 9.18 transcriptional regulator     |
| AS94_12210  |           | 8.22                             | 7.00 hypothetical protein          |
| AS94_12215  |           | 7.15                             | 5.65 hypothetical protein          |
| AS94_12220  |           | 9.85                             | 9.62 dut, DUTP pyrophosphatase     |
| AS94_12230  |           | 6.69                             | 6.41 hypothetical protein          |
| AS94_12240  |           | 8.84                             | 8.52 hypothetical protein          |
| AS94_12270  |           | 5.76                             | 6.56 DNA N-6-adenine-methyltransferase |
| AS94_12295  |           | 9.66                             | 9.80 hypothetical protein          |
| AS94_12300  |           | 5.72                             | 5.64 hypothetical protein          |
| AS94_12325  |           | 10.13                            | 10.26 hypothetical protein         |
| AS94_12330  |           | 6.36                             | 6.05 hypothetical protein          |
| AS94_12340  |           | 6.27                             | 7.58 hypothetical protein          |
| AS94_12345  |           | 11.88                            | 12.34 BRO-like protein             |
| AS94_12350  |           | 10.47                            | 10.70 hypothetical protein         |
| AS94_12355  |           | 8.09                             | 8.50 XRE family transcriptional regulator |
| AS94_12360  |           | 12.88                            | 12.46 transcriptional regulator    |
| AS94_12365  |           | 8.86                             | 8.90 \( \phi_{80x}\_gp05 \)         |
| AS94_12370  |           | 12.98                            | 13.02 repressor                    |
| AS94_12375  |           | 10.38                            | 10.92 integrase                    |
Table 3. DEGs down-regulated by φSA169.

| Gene Locus | Group                          | Log2(Fold Change) | Products                                      |
|-----------|--------------------------------|-------------------|-----------------------------------------------|
| AS94_03800| 301-188::φSA169 vs. 301-188    | −0.82             | cysteine protease                             |
| AS94_04675| 301-188::φSA169 vs. 301-188    | −0.39             | sdrD, hydrolase                               |
| AS94_05575| 301-188::φSA169 vs. 301-188    | −0.74             | lacE, PTS lactose transporter subunit IIBC    |
| AS94_05680| 301-188::φSA169 vs. 301-188    | −1.11             | lacF, PTS lactose transporter subunit IIA     |
| AS94_05855| 301-188::φSA169 vs. 301-188    | −0.81             | lacD, tagatose-bisphosphate aldolase          |
| AS94_05990| 301-188::φSA169 vs. 301-188    | −0.85             | lacC, tagatose-6-phosphate kinase             |
| AS94_06055| 301-188::φSA169 vs. 301-188    | −1.09             | lacB, galactose-6-phosphate isomerase         |
| AS94_06060| 301-188::φSA169 vs. 301-188    | −0.76             | lacA, galactose-6-phosphate isomerase         |
| AS94_06110| 301-188::φSA169 vs. 301-188    | −0.54             | nikA, nickel ABC transporter                  |
| AS94_07070| host genes                     | −0.39             | gntK, glucokinase                             |
| AS94_08235| host genes                     | −0.48             | pFB, phosphofructokinase                      |
| AS94_08280| host genes                     | −0.48             | hypothetical protein                          |
| AS94_09210| host genes                     | −0.58             | general stress protein                        |
| AS94_10090| host genes                     | −0.86             | murein hydrolase regulator lrgA, LrgA         |
| AS94_10365| host genes                     | −0.78             | sialic acid transporter                       |
| AS94_10370| host genes                     | −0.84             | nanA, N-acetylneuraminate lyase               |
| AS94_10375| host genes                     | −0.37             | N-acetylmuramoylkinase                        |
| AS94_11050| host genes                     | −0.67             | trvP, PTS ascorbate transporter subunit IIA    |
| AS94_11645| host genes                     | −0.38             | pyridoxal biosynthesis protein                |
| AS94_12280| host genes                     | −0.90             | hypothetical protein                          |
| AS94_12575| host genes                     | −0.43             | tldC, delta-hemolysin                         |
| AS94_13070| the mutual prophage in SA169   | −1.47             | autolysin                                     |
| AS94_13075| the mutual prophage in SA169   | −1.69             | holin                                         |
| AS94_13080| the mutual prophage in SA169   | −1.68             | hypothetical protein                          |
| AS94_13090| the mutual prophage in SA169   | −2.18             | hypothetical protein                          |
| AS94_13095| the mutual prophage in SA169   | −1.70             | hypothetical protein                          |
| AS94_13100| the mutual prophage in SA169   | −1.53             | minor structural protein                      |
| AS94_13110| the mutual prophage in SA169   | −1.72             | peptidase                                     |
| AS94_13115| the mutual prophage in SA169   | −1.90             | holin                                         |
| AS94_13120| the mutual prophage in SA169   | −1.62             | tail protein                                  |
| AS94_13130| the mutual prophage in SA169   | −2.75             | hypothetical protein                          |
| AS94_13135| the mutual prophage in SA169   | −1.42             | tail protein                                  |
| AS94_13140| the mutual prophage in SA169   | −2.01             | tail protein                                  |
| AS94_13150| the mutual prophage in SA169   | −1.85             | hypothetical protein                          |
| AS94_13160| the mutual prophage in SA169   | −2.00             | hypothetical protein                          |
| AS94_13165| the mutual prophage in SA169   | −1.93             | phage capsid protein                          |
| AS94_13170| the mutual prophage in SA169   | −2.19             | ATP-dependent Clp protease ClpP               |
| AS94_13175| the mutual prophage in SA169   | −1.61             | portal protein                                |
| AS94_13180| the mutual prophage in SA169   | −1.71             | terminase                                     |
| AS94_13185| the mutual prophage in SA169   | −1.74             | terminase                                     |
| AS94_13190| the mutual prophage in SA169   | −2.02             | HNH endonuclease                              |
| AS94_13195| the mutual prophage in SA169   | −0.73             | transcriptional regulator                     |
| AS94_13200| the mutual prophage in SA169   | −0.89             | helicase                                      |
| AS94_13205| the mutual prophage in SA169   | −0.75             | hypothetical protein                          |
| AS94_13355| the mutual prophage in SA169   | −0.46             | antirepressor                                 |

3.4. The Impact of MRSA Genetic Background on Transcriptional Profiles

The overlapping DEGs of 300-169 vs. 301-188 and 300-169 vs. 301-188 excluding the impact of φSA169 (Figure 4). There were 555 (519 + 36) DEGs up-regulated (Figure 4a, Table S7) and 546 (523 + 23) DEGs down-regulated (Figure 4b, Table S8) in these two comparisons. The up-regulated DEGs included 26 genes of φSA169 and 6 genes of the mutual prophage in 300-169 and 301-188 (Table S7). The down-regulated DEGs included 3 genes of φSA169 and 18 genes of the mutual prophage (Table S8).

3.5. DEGs Impacted by Both φSA169 and MRSA Genetic Backgrounds

There were 36 (Figure 4a, Table S9) and 23 (Figure 4b, Table S10) DEGs up- and down-regulated in all three comparisons, respectively. It indicated that these DEGs were affected by both φSA169 and the genetic backgrounds of 300-169 and 301-188. The up-regulated DEGs included 26 genes in φSA169 and 10 other staphylococcal genes (Table S9).
down-regulated DEGs consisted of 10 genes in the mutual prophage and 13 MRSA genes (Table S10).

3.6. Global KEGG Analyses of DEG Profiles

To understand the gene functions and pathways associated with the persistent outcomes, we classified the DEGs using the KEGG pathways mapper tool (Figure 5). In 301-188::φSA169, a significant number of genes were down-regulated compared to 301-188 (e.g., carbohydrate metabolism and membrane transport; Figure 5a). In 300-169, genes involved in carbohydrate and amino acids metabolisms, metabolism of cofactors and vitamins, and membrane transport were mainly differentially expressed vs. 301-188 (Figure 5b). Some pathways were found up-regulated in 300-169 vs. 301-188 (e.g., glycan biosynthesis and metabolism, transcription, and drug resistance; Figure 5b). The KEGG analysis profile of 300-169 vs. 301-188::φSA169 (Figure 5c) was similar to 300-169 vs. 301-188 (Figure 5b), suggesting the significant differences may be due to the different genetic backgrounds.

![Figure 5](https://example.com/figure5.png)

**Figure 5.** KEGG analysis of the DEGs from (a) 301-188::φSA169 vs. 301-188; (b) 300-169 vs. 301-188; (c) 300-169 vs. 301-188::φSA169. 301-188::φSA169 vs. 301-188 had significantly more DEGs down-regulated than the DEGs up-regulated, and most DEGs were related to metabolic pathways. 300-169 vs. 301-188 and 300-169 vs. 301-188::φSA169 had similar KEGG analysis profiles; most of the DEGs were involved in metabolism.
3.7. φSA169-Specific KEGG Analyses

The overlapping DEGs of 301-188::φSA169 vs. 301-188 and 300-169 vs. 301-188 might represent the genes regulated explicitly by φSA169 (Figure 4). The KEGG profile of the overlapping DEGs indicated that most of these genes were involved in metabolic pathways (Figure 6). For instance, the DEGs of fatty acid biosynthesis (fabFH), purine metabolism (purA), and RNA degradation (AS94_08925) were up-regulated by φSA169. Among the down-regulated DEGs by φSA169, many of them belonged to galactose metabolism (lacABCDEF) and phosphotransferase system (PTS) (treP, pfkB) (Figure 6).

![Figure 6](image)

**Figure 6.** KEGG analysis of the DEGs impacted by φSA169. Fatty acid biosynthesis had the most genes up-regulated, compared to the other pathways, while galactose metabolism and phosphotransferase system (PTS) were the pathways that had most genes down-regulated.

3.8. Verification of the Selected DEGs

DEGs that were up-/down-regulated in both comparisons 301-188::φSA169 vs. 301-188 and 300-169 vs. 301-188 were thought to be significantly impacted by φSA169. The expression of four DEGs (fabH, purA, lacF, and treP) involved in different KEGG pathways was selected to verify the RNA-seq results using qRT-PCR. Primers for the selected genes are listed in Table S11. Genes fabH/purA and lacF/treP represented significantly up- and down-regulated DEGs by φSA169, respectively. The fold changes of the four genes determined by the qRT-PCR were similar to the results obtained in the RNA-seq assays (Figure 7).

![Figure 7](image)

**Figure 7.** Verification of selected genes fabH, purA, lacF, and treP using qRT-PCR. The fold changes of the selected genes determined by qRT-PCR (white bars) were consistent with the values obtained by RNA-seq (black bars) in both comparisons of (a) 301-188::φSA169 vs. 301-188 and (b) 300-169 vs. 301-188.
4. Discussion

Many phages carry virulence factors that significantly contribute to genome variation, pathogenesis, and antibiotic resistance in *S. aureus* [7,19,20]. Despite the obvious importance of phages, studies on the interactions between phage and MRSA persistent outcome are limited. Recently, we demonstrated that the lysogenization of clinical RB 301-188 strain with phage φSA169 resulted in persistent phenotypes in vitro and in an experimental endocarditis model [11]. Thus, the current study was designed to determine the impact of φSA169 on genetic factors that may contribute to persistent MRSA endovascular infections.

The RNA-seq results revealed that MRSA host genes up-regulated by φSA169 were mainly involved in fatty acid biosynthesis (*fabF* and *fabH*), purine (*purA*), pyrimidine (*AS94_12220*), and RNA degradation (*AS94_08925*). Both *fabF* and *fabH* encode essential enzymes for fatty acid biosynthesis in many pathogens, including *S. aureus* [21]. Fatty acids are crucial hydrophobic components of membrane lipids and are important metabolic energy sources in bacteria [22]. It has been reported that defected unsaturated fatty acid biosynthesis in *Streptococcus mutans* results in attenuated virulence (e.g., less transmissible, less carious lesions) in a rodent model of dental caries [23]. In addition, fatty acid biosynthesis contributes to virulence in Group B *Streptococcus* (GBS) [24]. Importantly, fatty acid biosynthesis pathway inhibition has been investigated as a possible antimicrobial agent in bacteria [25]. In the current study, significantly higher expressions of *fabF* and *fabH* were observed in the φSA169-carrying strains, which may result in survival advantage and consequent persistence.

As a member of pur regulon, *purA* encodes the enzyme that catalyzes the conversion of inosine-5-phosphate (IMP) to adenylosuccinate [26]. We and others have previously shown that purine biosynthesis promotes virulence and persistence in *S. aureus* [14,26–28]. For instance, the inactivation of *purA* causes the lower expression of a broad spectrum of genes (e.g., energy production and conversion) and attenuates the ability of *S. aureus* to cause kidney infection in mice [27]. Li et al. reported that higher purine biosynthesis production correlates with persistent outcomes in an experimental MRSA endocarditis model [14]. In addition, several studies demonstrated that the inactivation of purine biosynthesis repressor, *purK*, leads to a greater amount of secreted virulence factors and hypervirulence in the murine model of *S. aureus* bacteremia model [26,28]. In the current study, the purine biosynthesis gene, *purA*, was found to be significantly up-regulated by φSA169. Therefore, φSA169-related higher *purA* expression might contribute to the persistent outcomes we observed in our recent study [11].

It is also interesting that φSA169 significantly down-regulated several genes related to the galactose metabolism. Galactose is a common monosaccharide used by organisms [29]. *S. aureus* employs lac operon to import and metabolize galactose [30]. In a previous study, the down-regulation of lac operon was observed in a *rpoB* (A621E) mutant *S. aureus* strain that had decreased susceptibility to vancomycin compared to the parental strain [31]. Therefore, down-regulated lac operon in the φSA169-carrying strains might contribute to the persistent outcomes with VAN treatment in vivo [11]. However, more research into galactose metabolism and its role in pathogenesis and persistence in *S. aureus* is needed. The RNA-seq displayed down-regulation of the phosphotransferase system (PTS) by φSA169. It has been demonstrated that the PTS plays an important role in carbohydrate transport, and the regulation of sugar utilization genes, which further contributes to overall metabolic efficiency in Gram-positive bacteria [32,33]. Gera et al. reported that deleting ptsI that encodes cytosolic enzyme I (EI) (ΔptsI) in group A *Streptococcus* (GAS) strains resulted in a hypervirulent phenotype compared to their respective wild-type strains (e.g., significantly increased skin lesion severity and size) in a murine model of disseminating skin and soft tissue infection [33]. Thus, PTS appears to reduce the virulence of GAS skin infection. However, a conflict phenotype of interrupted ptsI in *S. aureus* was reported with an attenuated virulence compared to its wild-type strain in a systemic infection model [34]. We suspect this discrepancy is possibly due to (i) the PTS regulation of virulence factors in GAS vs. *S. aureus* and (ii) the animal models used (skin and soft tissue infection vs.
systemic infection). Importantly, galactose is one of the carbohydrates that utilizes PTS [35]. Thus, down-regulated PTS in ϕSA169-carrying strains might be correlated with the lower expression of galactose metabolism genes. Detailed studies are needed to define the specific role of PTS, and the interaction between PTS and galactose, in persistent MRSA endovascular infection.

In this study, we also observed that some genes within the mutual prophage in both 300-169 and 301-188 strains were negatively impacted by ϕSA169, which suggested that the mutual prophage genes might be another ϕSA169-derived genetic factor that participated in the PB outcomes. It has been reported that the pathogenesis of *S. aureus* Newman requires the participation of its all four prophages [7]. Thus, multiple prophages might have combined effects on virulence and pathogenesis in *S. aureus*. Therefore, ϕSA169 might contribute to the PB outcomes by mediating the gene expression of the mutual prophage.

Besides the impact of ϕSA169 on genetic factors in the MRSA host genes and the mutual prophage, the different genetic backgrounds between 300-169 and 301-188 strains might also play a role in the persistent outcomes (Figure S1). We have previously demonstrated that key global regulators were differently expressed in 300-169 and 301-188 [11,14]. These differences may impact downstream virulence factors, subsequently contributing to the persistent outcome.

We recognize that there were some significant limitations in the current study. For instance, we only studied a PB 300-169 WT (300-169) containing ϕSA169, RB 301-188 WT (301-188) in the absence of ϕSA169, and 301-188 WT with ϕSA169 lysogenization (301-188::ϕSA169) in the current and previous research [11]. It would be important to verify the genetic impact of ϕSA169 using ϕSA169 deletion in the PB 300-169 strain background. In addition, it would be interesting to study the combinational effect of VAN with ϕSA169 on the MRSA host and ϕSA169 genes, which may demonstrate how ϕSA169 mediates the response to VAN treatment in the IE model [11]. Therefore, further investigations are needed to address these limitations.

5. Conclusions

In this study, we explored the impact of prophage ϕSA169 on genetic factors, which might play an essential role in MRSA-persistent endovascular infection. The results highlighted that ϕSA169 contributed to PB outcomes mainly through mediating metabolisms, especially the up-regulation of fatty acid biosynthesis and down-regulation of galactose metabolism and PTS. In addition, the mutual prophage in both 300-169 and 301-188 strains and different genetic backgrounds of these two strains might also be the genetic factors that contribute to the PB outcomes.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/genes13091527/s1, Table S1: Up-regulated DEGs in 301-188::ϕSA169 vs. 301-188; Table S2: Down-regulated DEGs in 301-188::ϕSA169 vs. 301-188; Table S3: Up-regulated DEGs in 300-169 vs. 301-188; Table S4: Down-regulated DEGs in 300-169 vs. 301-188; Table S5: Up-regulated DEGs in 300-169 vs. 301-188::ϕSA169; Table S6: Down-regulated DEGs in 300-169 vs. 301-188::ϕSA169; Table S7: Up-regulated DEGs in both 300-169 vs. 301-188 and 300-169 vs. 301-188::ϕSA169; Table S8: Down-regulated DEGs in both 300-169 vs. 301-188 and 300-169 vs. 301-188::ϕSA169; Table S9: DEGs up-regulated by both ϕSA169 and MRSA genetic backgrounds; Table S10: DEGs down-regulated by both ϕSA169 and MRSA genetic backgrounds; Table S11: Primers for qRT-PCR confirmation; Figure S1: KEGG analysis of the DEGs impacted by the distinct genetic backgrounds of 300-169 and 301-188.

**Author Contributions:** Conceptualization, Y.Q.X.; Formal analysis, Y.L., L.C. and Y.Q.X.; Investigation, Y.L. and F.Z.; Supervision, Y.Q.X.; Writing—original draft, Y.L. and Y.Q.X.; Writing—reviewing and editing, L.C. and A.S.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was funded by the National Institutes of Health/National Institute of Allergy and Infectious Diseases grant R01AI139244 to Y.Q.X.

**Institutional Review Board Statement:** Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.

References
1. Fowler, V.G., Jr.; Miro, J.M.; Hoern, B.; Cabell, C.H.; Abrutyn, E.; Rubinstein, E.; Corey, G.R.; Spelman, D.; Bradley, S.F.; Barsic, B.; et al. *Staphylococcus aureus* endocarditis: A consequence of medical progress. *JAMA* 2005, 293, 3012–3021. [CrossRef] [PubMed]
2. Klevens, R.M.; Morrison, M.A.; Nadle, J.; Petit, S.; Gershman, K.; Ray, S.; Harrison, L.H.; Lynfield, R.; Dumyati, G.; Townes, J.M.; et al. Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States. *JAMA* 2007, 298, 1763–1771. [CrossRef] [PubMed]
3. Fowler, V.G., Jr.; Sakoulas, G.; McIntyre, L.M.; Meka, V.G.; Arbeit, R.D.; Cabell, C.H.; Stryjewski, M.E.; Eliopoulos, G.M.; Keller, L.B.; Corey, G.R.; et al. Persistent bacteremia due to methicillin-resistant *Staphylococcus aureus* infection is associated with *agr* dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. *J. Infect. Dis.* 2004, 190, 1140–1149. [CrossRef] [PubMed]
4. Xiong, Y.Q.; Fowler, V.G.; Yeaman, M.R.; Perdreau-Remington, F.; Kreiswirth, B.N.; Bayer, A.S. Phenotypic and genotypic characteristics of persistent methicillin-resistant *Staphylococcus aureus* bacteremia in vitro and in an experimental endocarditis model. *J. Infect. Dis.* 2009, 199, 201–208. [CrossRef]
5. Seidl, K.; Chen, L.; Bayer, A.S.; Hady, W.A.; Kreiswirth, B.N.; Xiong, Y.Q. Relationship of *agr* expression and function with virulence and vancomycin treatment outcomes in experimental endocarditis due to methicillin-resistant *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 2011, 55, 5631–5639. [CrossRef] [PubMed]
6. Li, L.; Yeaman, M.R.; Bayer, A.S.; Xiong, Y.Q. Phenotypic and genotypic characteristics of methicillin-resistant *Staphylococcus aureus* (MRSA) related to persistent endovascular infection. *Antibiotics* 2019, 8, 71. [CrossRef]
7. Bae, T.; Baba, T.; Hiramatsu, K.; Schneewind, O. Prophages of *Staphylococcus aureus* Newman and their contribution to virulence. *Mol. Microbiol.* 2006, 62, 1035–1047. [CrossRef]
8. Fernandez, L.; Gonzalez, S.; Campelo, A.B.; Martinez, B.; Rodriguez, A.; Garcia, P. Low-level predation by lytic phage phiPLA-RODI promotes biofilm formation and triggers the stringent response in *Staphylococcus aureus*. *Sci. Rep.* 2017, 7, 40965. [CrossRef]
9. Fernandez, L.; Gonzalez, S.; Quiles-Puchalt, N.; Gutierrez, D.; Penades, J.R.; Garcia, P.; Rodriguez, A. Lysogenization of *Staphylococcus aureus* RN450 by phages *Staphylococcus aureus* on *sarA* and *agr* expression and function with *agr* dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. *J. Infect. Dis.* 2005, 293, 3012–3021. [CrossRef] [PubMed]
10. El Haddad, L.; Moineau, S. Characterization of a novel Panton-Valentine leukocidin (PVL)-encoding staphylococcal phage and its naturally PVL-lacking variant. *Appl. Environ. Microbiol.* 2013, 79, 2828–2832. [CrossRef]
11. Li, L.; Wang, G.; Li, Y.; Francois, P.; Bayer, A.S.; Chen, L.; Seidl, K.; Cheung, A.; Xiong, Y.Q. Impact of the novel prophage *phiSA169* on persistent methicillin-resistant *Staphylococcus aureus* endocardial infection. *mSystems* 2020, 5, 3. [CrossRef] [PubMed]
12. Hernandez, D.; Seidl, K.; Corvaglia, A.R.; Bayer, A.S.; Xiong, Y.Q.; Francois, P. Genome sequences of sequence type 45 (ST45) persistent methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia strain 301-169 and ST45 resolving MRSA bacteremia strain 301-188. *Genome Announcements* 2014, 2, 2. [CrossRef]
13. Li, L.; Wang, G.; Cheung, A.; Abdelhady, W.; Seidl, K.; Xiong, Y.Q. MgrA governs adherence, host cell interaction, and virulence in a murine model of bacteremia due to *Staphylococcus aureus*. *J. Infect. Dis.* 2019, 220, 1019–1028. [CrossRef] [PubMed]
14. Li, L.; Abdelhady, W.; Donegan, N.P.; Seidl, K.; Cheung, A.; Zhou, Y.F.; Yeaman, M.R.; Bayer, A.S.; Xiong, Y.Q. Role of purine biosynthesis in persistent methicillin-resistant *Staphylococcus aureus* infection. *J. Infect. Dis.* 2018, 218, 1367–1377. [CrossRef]
15. Langmead, B.; Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* 2012, 9, 357–359. [CrossRef] [PubMed]
16. Kanehisa, M.; Sato, Y.; Kawashima, M. KEGG mapping tools for uncovering hidden features in biological data. *Protein Sci.* 2012, 31, 47–53. [CrossRef] [PubMed]
17. Abdelhady, W.; Chen, L.; Bayer, A.S.; Seidl, K.; Yeaman, M.R.; Kreiswirth, B.N.; Xiong, Y.Q. Early agr activation correlates with vancomycin treatment failure in multi-clonotype MRSA endovascular infections. *J. Antimicrob. Chemother.* 2015, 70, 1443–1452. [CrossRef]
18. Abdelhady, W.; Bayer, A.S.; Seidl, K.; Moormeier, D.E.; Bayles, K.W.; Cheung, A.; Yeaman, M.R.; Xiong, Y.Q. Impact of vancomycin on sarA-mediated biofilm formation: Role in persistent endovascular infections due to methicillin-resistant *Staphylococcus aureus*. *J. Infect. Dis.* 2014, 209, 1231–1240. [CrossRef]
19. Novick, R.P. Mobile genetic elements and bacterial toxinoses: The superantigen-encoding pathogenicity islands of *Staphylococcus aureus*. *Plasmid* 2003, 49, 93–105. [CrossRef]
20. Kondo, K.; Kawano, M.; Sugai, M. Distribution of antimicrobial resistance and virulence genes within the prophage-associated regions in nosocomial pathogens. *mSphere* 2021, 6, e0045221. [CrossRef]
21. Payne, D.J.; Warren, P.V.; Holmes, D.J.; Ji, Y.; Lonsdale, J.T. Bacterial fatty-acid biosynthesis: A genomics-driven target for antibacterial drug discovery. *Drug Discov. Today* 2003, 6, 537–544. [CrossRef]
22. Fujita, Y.; Matsuoka, H.; Hirooka, K. Regulation of fatty acid metabolism in bacteria. *Mol. Microbiol.* 2007, 66, 829–839. [CrossRef]
23. Fozo, E.M.; Scott-Anne, K.; Koo, H.; Quivey, R.G., Jr. Role of unsaturated fatty acid biosynthesis in virulence of *Streptococcus mutans*. *Infect. Immun.* 2007, 75, 1537–1539. [CrossRef] [PubMed]

24. Yamamoto, Y.; Pargade, V.; Lambet, G.; Gaudu, P.; Thomas, F.; Texereau, J.; Gruss, A.; Trieu-Cuot, P.; Poyart, C. The Group B *Streptococcus* NADH oxidase Nox-2 is involved in fatty acid biosynthesis during aerobic growth and contributes to virulence. *Mol. Microbiol.* 2006, 62, 772–785. [CrossRef] [PubMed]

25. Wang, J.; Soisson, S.M.; Young, K.; Shoop, W.; Kodali, S.; Galgoci, A.; Painter, R.; Parthasarathy, G.; Tang, Y.S.; Cummings, R.; et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. *Nature* 2006, 441, 358–361. [CrossRef] [PubMed]

26. Sause, W.E.; Balasubramanian, D.; Intron, I.; Copin, R.; Sullivan, M.J.; Sommerfield, A.; Chan, R.; Dhabaria, A.; Askenazi, M.; Uberheide, B.; et al. The purine biosynthesis regulator PurR moonlights as a virulence regulator in *Staphylococcus aureus*. *Proc. Natl. Acad. Sci. USA* 2019, 116, 13563–13572. [CrossRef]

27. Lan, L.; Cheng, A.; Dunman, P.M.; Missiakas, D.; He, C. Golden pigment production and virulence gene expression are affected by metabolisms in *Staphylococcus aureus*. *J. Bacteriol.* 2010, 192, 3068–3077. [CrossRef]

28. Goncheva, M.I.; Flannagan, R.S.; Sterling, B.E.; Laakso, H.A.; Friedrich, N.C.; Kaiser, J.C.; Watson, D.W.; Wilson, C.H.; Sheldon, J.R.; McGavin, M.J.; et al. Stress-induced inactivation of the *Staphylococcus aureus* purine biosynthesis repressor leads to hypervirulence. *Nat. Commun.* 2019, 10, 775. [CrossRef]

29. Chai, Y.; Beauregard, P.B.; Vlamakis, H.; Losick, R.; Kolter, R. Galactose metabolism plays a crucial role in biofilm formation by *Bacillus subtilis*. *mBio* 2012, 3, e00184-12. [CrossRef]

30. Miailau, L.; Hunter, W.N.; McSweeney, S.M.; Leonard, G.A. Structures of *Staphylococcus aureus* D-tagatose-6-phosphate kinase implicate domain motions in specificity and mechanism. *J. Biol. Chem.* 2007, 282, 19948–19957. [CrossRef]

31. Cui, L.; Isii, T.; Fukuda, M.; Ochiai, T.; Neoh, H.M.; Camargo, I.L.; Watanabe, Y.; Shoji, M.; Hishinuma, T.; Hiramatsu, K. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 2010, 54, 5222–5233. [CrossRef] [PubMed]

32. Deutscher, J.; Francke, C.; Postma, P.W. How phosphotransferase system-related protein phosphorylation regulates carbohydrate metabolism in bacteria. *Microbiol. Mol. Biol. Rev.* 2006, 70, 999–1031. [CrossRef] [PubMed]

33. Gera, K.; Le, T.; Jamin, R.; Eichenbaum, Z.; Mcelver, K.S. The phosphoenolpyruvate phosphotransferase system in group A *Streptococcus* acts to reduce streptolysin S activity and lesion severity during soft tissue infection. *Infect. Immun.* 2014, 82, 1192–1204. [CrossRef] [PubMed]

34. Kok, M.; Bron, G.; Erni, B.; Muhija, S. Effect of enzyme I of the bacterial phosphoenolpyruvate: Sugar phosphotransferase system (PTS) on virulence in a murine model. *Microbiology* 2003, 149, 2645–2652. [CrossRef]

35. Egan, J.B.; Morse, M.L. Carbohydrate transport in *Staphylococcus aureus* I. Genetic and biochemical analysis of a pleiotropic transport mutant. *Biochim. Biophys. Acta* 1965, 97, 310–319. [CrossRef]